FDA Clears Tildrakizumab (Ilumya) for Plaque Psoriasis FDA Clears Tildrakizumab (Ilumya) for Plaque Psoriasis

Tildrakizumab-asmn, a selective interleukin-23 p19 inhibitor given by subcutaneous injection, was shown to be effective for chronic plaque psoriasis in two phase 3 trials.FDA Approvals

Source: Medscape Medical News Headlines - March 21, 2018 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news